New England Journal of Medicine· 2015Q1
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- 2,291citations
- Q1SCImago
- 2015year
Short summary
In a 78-week trial of high-risk patients on statins, alirocumab reduced LDL cholesterol by 62% vs. placebo and showed a trend towards fewer major cardiovascular events (1.7% vs. 3.3%).
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Surgery
SurgeryMedicine